Cyclosporine A and adverse effects on organs: Histochemical studies

Progress in Histochemistry and Cytochemistry

Volumn 39, Issue 2, 2004, Pages 85-128

  Rezzani, Rita ^a  

^a Anatomy Section   (Italy)

Author keywords

AP; Calcineurin; CsA; Dendritic cells; ED1 and ED2 antibodies; Heart; Hepatotoxicity; Hypertension; Kidney; Light and electron microscopy; Liver; Nephrotoxicity; Nervous system; NFAT; Pancreas; Phosphatase acid; T cells; Thymus; TRPM1 and TRPM2 antibodies

Indexed keywords

BROMOCRIPTINE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CYCLOSPORIN A; CYTOCHROME P450; DANAZOL; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; METOCLOPRAMIDE; NICARDIPINE; NUCLEAR FACTOR; PHENOBARBITAL; PHENYTOIN; RIFABUTIN; RIFAMPICIN; TACROLIMUS; TRANSCRIPTION FACTOR; VERAPAMIL;

ANEMIA; CANCER; DRUG ERUPTION; DRUG METABOLISM; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; GLUCOSE INTOLERANCE; GRAPEFRUIT JUICE; HIRSUTISM; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFECTION; LYMPHOPROLIFERATIVE DISEASE; MORPHOLOGY; MYOSITIS; NEPHROTOXICITY; NEUROTOXICITY; ORGAN TRANSPLANTATION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STRUCTURE ANALYSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THYMUS;

EID: 3142604803     PISSN: 00796336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.proghi.2004.04.001     Document Type: Article

References (189)

1. Altschuh D. Cyclosporin A as a model antigen. immunochemical and structural studies J. Mol. Recogn. 15:2002;277-285
2. Andoh T.F., Burdmann E.A., Bennett W.M. Nephrotoxicity of immunosuppressive drugs. experimental and clinical observations Semin. Nephrol. 17:1997;34-45
3. Atkinson K., Biggs J., Darveniza P., Boland J., Concannon A., Dodds A. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation. 38:1984;34-37
4. Ayanoglou C.M., Lesty C. Cyclosporin A-induced gingival overgrowth in the rat. a histological, ultrastructural and histomorphometric evaluation J. Periodontol. Res. 34:1999;7-15
5. Baldwin W.M., Hutchison I.F., Meijer C.J.L.M., Tilney N.L. Immune responses to organ allografts. Marked decrease in medullary thymocytes and splenic T lymphocytes after cyclosporin A treatment. Transplantation. 31:1981;117-120
6. Belendiuk G., Solch S. Cyclosporine in neurological autoimmune disease. Clin. Neuropharmacol. 11(suppl. 4):1988;291-302
7. Benigni A., Bruzzi I., Mister M., Azzollini N., Gaspari F., Perico N., Gotti E., Bertani T., Remuzzi G. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int. 55:1999;674-685
8. Bennet W.M., Porter G.A. Cyclosporine-associated hypertension. Am. J. Med. 85:1988;131-133
9. Beschorner W.E., Armas O.A. Loss of medullary dendritic cells in the thymus after cyclosporine and irradiation. Cell. Immunol. 132:1991;505-514
10. Beschorner W.E., Namnoum J.D., Hess A.D., Shinn C.A., Santos G.W. Cyclosporin A and the thymus. Immunopathol. Am. J. Pathol. 126:1987;487-496
11. Beschorner W.E., Di Gennaro K.A., Hess A.D., Santos G.W. Cyclosporine and the thymus. influence of irradiation and age on thymic immunopathology and recovery Cell. Immunol. 110:1987;350-364
12. Beschorner W.E., Olson J.L., Hess A.D., Di Gennaro K.A., Santos G.W. Cyclosporine-induced cell-mediated injury of the thymic medullary epithelium. Transplantation. 45:1988;797-803
13. Bianchi S., Bigazzi R., Baldari G., Scherri G., Campese V.M. Diurnal variations of blood pressure and microalbinuria in essential hypertension. Am. J. Hypertens. 7:1994;23-29
14. Bianchi R., Rodella L., Rezzani R. Cyclosporine A up-regulates expression of matrix metalloproteinase 2 and vascular endothelial growth factor in rat heart. Int. Immunopharmacol. 3:2003;423-433
15. Blair J.T., Thompson A.W., Whiting P.H., Davidson R.J.L., Simpson J.G. Toxicity of the immune suppressant cyclosporine A in the rat. J. Pathol. 138:1982;163-178
16. Borel J.F., Feurer C., Gubler H.U., Stahelin H. Biological effects of CsA. a new antilymphocytic agent Agents Actions. 6:1976;468-475
17. Bork R.W., Muto T., Beaune P.H., Srivastava P.K., Lloyd R.S., Guengerich F.P. Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J. Biol. Chem. 264(suppl. 2):1989;910-919
18. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., Hors J., Mihatsch M.J., Paillard M., Chaussain J.L., Bach J.F. Factors associated with early remission of type I diabetes in children treated with cyclosporine. New Engl. J. Med. 318:1988;663-670
19. Calne R.Y. Immunological tolerance. the liver effect J. Gastroenterol. Hepatol. Rev. 17:2002;488-490
20. Calne R.Y., White D.J., Thiru S., Evans D.B., McMaster P., Dunn D.C., Craddock G.N., Pentlow B.D., Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 2:1978;1323-1327
21. Calne R.Y., Rolles K., White D.J.G. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases and 2 livers. Lancet. 2:1979;1033-1041
22. Canadian Multicenter Transplant Study Group, 1986. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. New Engl. J. Med. 314, 1219-1225.
23. Cheney R.T., Sprent J. Capacity of cyclosporine to induce autograft-versus-host disease and impair intrathymic T cell differentiation. Transplant. Proc. 17:1985;528-530
24. Chiara M.D., Sobrino F. Modulation of the inhibition of respiratory burst in mouse macrophages by cyclosporin A. effect of in vivo treatment glucocorticoids and the state of activation of cell Immunology. 72:1991;133-137
25. Christians U., Sewing K.F. Cyclosporin metabolism in transplant patients. Pharmacol. Ther. 57:1993;291-345
26. Chung E., Dvzorozniak M.T., Van Woert M.H., Li H.C. Regional distribution of calcium/calmodulin-dependent phosphatase activity of calcineurin in rat brain. Res. Commun. Chem. Pathol. Pharmacol. 64:1989;357-371
27. Cohen S.M. Current immunosuppression in liver transplantation. Ther. Rev. 9(2):2002;119-125
28. Colic M., Jovanovic S., Mitrovic S., Dujic A. Immunohistochemical identification of six cytokeratin-defined subset of the rat thymic epithelial cells. Thymus. 13:1989;175-185
29. Colic M., Popovic L.J., Gasic S., Dragojevic V., Milicevic N.M., Matanovic D., Dujic A. Immunohistochemical characterization of rat thymic non lymphoid cells. Macrophages and granulocytes defined by monoclonal antibodies. Immunology. 69:1990;416-422
30. Collins T.L., Deckert M., Altman A. View on Vav. Immunol. Today. 18:1997;221-225
31. Combalbert J., Fabre I., Fabre G., Dalet I., Derancourt J., Cano J.P., Maurel P. Metabolism of cyclosporine A. IV. Purification and identification of the rifampicin inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily Drug Metab. Dispos. 17:1989;197-207
32. Cornish J., Vanderwee M., Findon G., Miller T. Significance of cyclosporin-A-associated renal surface irregularities. Br. J. Exp. Pathol. 69:1988;839-845
33. Dardenne M., Savino W., Feutren G., Bach J.F. Stimulatory effects of cylosporin A on human and mouse thymic epithelial cells. Eur. J. Immunol. 17:1987;275-279
34. Davies D.R., Bittmann I., Pardo J. Histopathology of calcineurin inhibitor-induced nephrotoxicity. Transplantation. 69(12):2000;SS11-SS13
35. De Groen P.C. Hypothesis. cyclosporine, low-density lipoproteins and cholesterol Mayo Clin. Proc. 63:1988;1012-1021
36. De Groen P.C., Aksamit A.J., Rakela J., Froben G.S., Krom R.A.F. Central nervous system toxicity after liver transplantation. the role of cyclosporine and cholesterol New Engl. J. Med. 317:1987;861-886
37. De Luca H.F. The vitamin D story. a collaborative effort of basic science and clinical medicine Faseb J. 2:1988;224-236
38. De Wall E.J., Schuurman H.J., Hendriksen C., Elvers B., Van Dijk A., Van Loveren H. Effects of subcutaneous vs. intravenous administration of cyclosporin A on rat thymic histology and pharmacokinetics. Int. J. Immunopharmacol. 14:1992;1101-1105
39. De Wall E.J., Rademarkers L.H.P.M, Schuurman H.J., Van Loveren H., Vos J.G Ultrastructure of cortical epithelium or the rat thymus after in vivo exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). Arch. Toxicol. 67:1993;558-564
40. De Wall E.J., Radenmarkers L.H.P.M, Schuurman H.J., Vos J.G., Van Loveren H. Interdigitating cells in the rat thymus without epithelial cell loss during cyclosporine treatment and recovery. Toxicology. 110:1996;163-170
41. De Waal E.J., Schuurman H.J., Van Loveren H., Vos J.G. Differential effects of 2, 3, 7, 8-tetrachlorodibenzo-P-dioxin, bis (Tri-N-butyltin) oxide cyclosporine on thymus histophysiology. Crit. Rev. Toxocol. 27(suppl. 4):1997;318-430
42. Dijkstra C.D., Dopp E.A., Joling P., Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid organs. distinct macrophages subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3 Immunology. 54:1985;589-597
43. Dindzans V.J., Wong P.Y., Mee A.V., Cheung F., Abecassis M., Cole E.H., Cohen Z., Levy G.A. Cyclosporine metabolites suppress T cell prolifertion induced by concanavalin A. Transplant. Proc. 19:1987;3490-3493
44. Drewe J., Beglinger C., Kissel T. The absorption of cyclosporin in the human gastrointestinal tract. Br. J. Clin. Pharmacol. 33:1992;39-43
45. Durkan A.M., Hodson E.M., Willis N.S., Craig J.C. Immunosuppressive agents in childhood nephrotic syndrome. a meta-analysis of randomized controlled trials Kidney Int. 59:2001;1919-1927
46. East C., Alivizatos P.A., Grundy S.M., Jones P.H., Farmer J.A. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. New Engl. J. Med. 318:1988;47-48
47. European Multicenter Trial Group, 1983. Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicenter trail. Lancet 986-989.
48. Famiglio L., Racusen L., Fivush B. CNS toxicity of cyclosporine in a rat model. Transplantation. 48:1989;316-321
49. Farnsworth A., Hall B.M., Ng A., Duggin G.G., Horvath J.S., Sheil A.G., Tiller D.J. Renal biopsy morphology in renal transplantation. Am. J. Surg. Pathol. 8:1984;243-252
50. Fidelus R.K., Ferguson R.M. The immunosuppressive action of cyclosporine (CsA) as evaluated in 24. h kinetics profiles Transplant. Proc. 15:1983;1921-1923
51. 2+ current ICRAC to InsP3 in Jurkat T-lymphocytes, pulmonary arthery endothelia and BRL-1 cells. Pflügers Arch. 440:2000;580-587
52. Frey F.J. Cyclosporin bei Autoimmunerkrankungen. Schweiz Med. Wochenschr. 120:1990;772-786
53. Garcia J.E.L., Rodrigues F.M., Lopez A.J., Arellano J.L.P. Action of cyclosporin A on mononuclear phagocytes. (Rev.) Invest. Allergol. Clin. Immunol. 6(suppl. 4):1996;222-231
54. Gauthier P., Helderman H. Cyclosporine avoidance. J. Am. Soc. Nephrol. 11:2000;1933-1936
55. Gijtenbeek J.M.M., Van De Bent M.J., Vecht C.J. Cyclosporine neurotoxicity. a review Rev. J. Neurol. 246:1999;339-346
56. Glazier A., Tutschka P.J., Farmer E. Studies on the immunobiology of syngeneic and autologous graft-vs.-host disease in cyclosporin-treated rats. Transplant. Proc. 15:1983;3035-3048
57. Guengerich F.P. Characterization of Human microsomal cytochrome P-450 enzymes. Annu. Rev. Pharmacol. Toxicol. 29:1989;241-264
58. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin. a specific cytosolic binding protein for cyclosporine A Science. 226:1984;544-547
59. Hansson M.J., Friberg H., Keep M.F., Wieloch T., Elmer T. Powerful cyclosporin inhibition of calcium-induced permeability transition in brain mitochondria. Brain. Res. 960(1-2):2003;99-111
60. Harris D.T., Kozumbo W.J., Cerutti P.A., Cerottini J.C. Mechanism of cyclosporin A-induced immunosuppression. Cyclosporin A inhibits receptor-mediated and non-receptor-mediated lymphokine production as well as interleukin-2-induced proliferation in cloned T lymphocytes. Cell. Immunol. 109:1987;104-114
61. Hartmann N.R., Jardine I. The in vitro activity, radioimmunoassay, and molecular weight of thirteen rabbit cyclosporine metabolite. Drug Metab. Dis. 15:1987;661-664
62. Hattori A., Kunz H.W., Gill T.J., Shinozuka H. Thymic and lymphoid changes and serum immunoglobulin abnormalities in mice receiving cyclosporine. Am. J. Pathol. 128:1987;111-120
63. Henke W., Jung K. Comparison of the effects of the immunosuppressive agents FK-506 and cyclosporin A on rat kidney mitochondria. Biochem. Pharmacol. 46:1993;829-832
64. Hess A.D., Horwitz L., Beschorner W.E., Santos G.W. Development of graft-vs.-host disease-like syndrome in cyclosporin-treated rats after syngeneic bone marrow transplantation. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J. Exp. Med. 161:1985;718-726
65. Hirakawa K., Ohkuma S., Kuriyama K. Functional and morphological changes of the exocrine pancreas in cyclosporin-treated rats. Eur. Surg. Res. 6:1991;292-302
66. Hirakawa K., Yoshimura N., Tsuchihasi Y., Mukainaka T., Ohkuma S., Kuriyama K., Oka T. Cyclosporine induced morphological changes in rat exocrine pancreas. Transplant. Proc. 26(suppl. 5):1994;2918-2921
67. Hiramine C., Hojo K., Matsumoto H. Abnormal distribution of T cells subsets in the thymus of cyclosporin A (CsA)-treated mice. Thymus. 11:1988;243-252
68. Horina J.H., Wirnsberger G.H., Kenner L., Holzer H., Krejs G.J. Increased susceptibility for CsA-induced hepatotoxicity in kidney graft recipients with chronic viral hepatitis C. Transplantation. 56:1993;1091-1094
69. Johansson A., Henricsson S., Moller E. A novel sulphate conjugate of cyclosporine occurring in high concentrations in vivo. Transplantation. 49:1990;619-622
70. Jurado F., Bellon J.M., Pareja J.A., Golitsin A., Millan L., Pasqual G., Bujan J. Effects of ischaemia-reperfusion and cyclosporin A on cardiac muscle ultrastructure. Histol. Histopatol. 13:1998;761-774
71. Kahan B. Cyclosporine. New Engl. J. Med. 321:1989;1725-1738
72. Kahan B., Van Buren C.T., Boileau M., Ried M., Payne W.D., Flechner S., Newburger J. Cyclosporin A tissue levels in a cadaveric renal allograft recipient. Transplantation. 35(suppl. 1):1983;96-99
73. Kanariou M., Huby R., Ladyman H., Colic M., Sivolapenko G., Lampert I., Ritter M. Immunosuppression with cyclosporine A alters the thymic microenvironment. Clin. Exp. Immunol. 78:1989;263-269
74. Kang D.H., Kim Y., Andoh T.F., Gordon K.L., Suga S., Mazzali M., Jefferson A., Hughes J., Bennett W., Schreiner G.F., Johnson R.J. Post-cyclosporine-mediated hypertension and nephropathy. amelioration by vascular endothelial growth factor Am. J. Physiol. Renal Physiol. 280:2001;727-736
75. Kennedy M.S., Deeg H.J., Siegel M. Acute renal toxicity with combined use of amphotericin B and cyclosporin after marrow transplantation. Transplantation. 35(suppl. 3):1983;211-215
76. Klintmalm G.B.G., Iwatsuki S., Starzl T.E. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet. 1:1981;470-477
77. Kosugi A., Zuniga-Pflucker J.C., Sharrow S.O., Kruisbeek A.M., Shearer G.M. Effect of cyclosporin A on lymphopoiesis. Developmental defects of immature and mature thymocytes in fetal thymus organ cultures treated with cyclosporine A. J. Immunol. 143:1989;3134-3140
78. Kronbach T., Fischer V., Meyer U.A. Cyclosporin metabolism in human liver. identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs Clin. Pharmacol. Ther. 247:1988;685-689
79. Kunzendorf U., Brockmoller J., Jochimsen F., Roots I., Offermann G. Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation. 48(suppl. 3):1989;531-532
80. Kunzendorf U., Waltz G., Brockmoeller J., Neumayer H.H., Jochimsen F., Roots L., Offermann G., Strom T.B. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation. 52:1991;280-284
81. Lake K.D. Management of drug interaction with the cyclosporine. Pharmacotherapie. 11:1991;110s-118s
82. Larsen, S., Brun, C., Duun, S., Lokkegaard, H., Thomsen, H.S., 1988. Early arteriolopathy following "high-dose" cyclosporine in kidney transplantation. APMIS (suppl. 4), 66-73.
83. Li J., Brown L.F., Hibberd M.G., Grossman J.D., Morgan J.P., et al. VEGF, flk-1 and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am. Physiol. Soc. 37:1996;1803-1811
84. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complex. Cell. 66:1991;807-815
85. Lorber M.I., Vanburen C.T., Flechner S.M., Williams C., Kahan B.D. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients. Tranplantation. 43(suppl. 1):1987;35-40
86. Lucke S., Radloff E., Laube R., Hahn H.J. Morphology of the endocrine pancreas in cyclosporine-treated glucose-intolerant wistar rats. Anat. Anzeiger. 172:1991;351-358
87. Martin F., Bedoya F.J. Mechanism of action of cyclosporin A on islet alpha- and beta cells. Effects on cAMP- and calcium-dependent pathways. Life Sci. 49:1991;1915-1921
88. Mason R.P., Leeds P.R., Jacob R.F., Houg C.J., Zhang K.J., Mason P.E., Ghuang D.M. Inibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J. Neurochem. 72:1999;1448-1456
89. Matsuda S., Shibasaki F., Takehana K., Mori H., Nishida E., Koyasus K. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation. Embr. Rep. 1(suppl. 5):2000;428-434
90. Mayer R.D., Berman S., Cockett A.T.K., Maines M.D. Differential effects of cyclosporin on hepatic and renal heme, cytochrome P-450 and drug metabolism. Possible role in nephrotoxicity of the drug. Biochem. Pharmacol. 38:1989;1001-1007
91. Mc Donald J.W., Goldberg M.P., Gwag B.J., Chi S.-I., Choi D.W. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann. Neurol. 40:1996;750-758
92. Mihatsch M.J., Wolff K. Consensus conference on cyclosporine A for psoriasis. Br. J. Dermatol. 126:1992;621-628
93. Mihatsch M.J., Thiel G., Spichtin H.P., Oberholzer M., Brunner F.P., Harder F., Olivieri V., Bremer R., Ryffel B., Stocklin E., Torhorst J., Gudat F., Zollinger H.U., Loertscher R. Morphological findings in kidney transplants after treatment with cyclosporine. Transplant. Proc. 15(suppl. 1):1983;2821-2830
94. Mihatsch M., Thiel G., Ryffel B. Cyclosporine nephrotoxicity. Adv. Nephrol. 17:1988;303-310
95. Mihatsch MJ, Gudat F, Ryffel B, Thiel G. Cyclosporine nephropathy. In: Renal Pathology: With Clinical and Functional Correlations. II eds. Brenner. Lippincott, Philadelphia, 1994.
96. Mihatsch MJ, Ryffel B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int. 1995;(suppl. 52):63-72.
97. Milicevic N.M., Milicevic Z. Enzyme-histochemical characterization of macrophages in the rat thymus, with special reference to metallophilic cells or the cortico-medullary zone of the normal rat thymus. J. Leukocyte Biol. 36:1984;761-769
98. Milicevic N.M., Milicevic Z. On the nature of the content in the PAS-positive macrophages of the rodent thymus. Thymus. 11:1988;257-259
99. Milicevic N.M., Milicevic Z. Ultrastructure of different types of thymic epithelial cells in normal and cyclosporin A-treated rats. Anat. Embryol. 196:1997;171-183
100. Milicevic N.M., Milicevic Z. Cyclosporin A-induced changes of the thymic microenvironment. A review of morphological studies. Histol. Histopathol. 13:1998;1183-1196
101. Milicevic N.M., Milicevic Z., Piletic O., Mujovic S. The metallophilic cells of the rat thymus. IRCS Med. Sci. 10:1982;950-959
102. Milicevic N.M., Milicevic Z., Colic M. Macrophages in the rat thymus after cyclosporin treatment. Histochemical, enzyme-histochemical and immunohistochemical study. Virchows Arch. B Cell. Pathol. 57:1989;237-244
103. Milicevic N.M., Milicevic Z., Colic M., Kamperdijk E.W.A., Hoefsmit E.C.M. Ultrastructural study of macrophages of the rat thymus after cyclosporin treatment. Thymus. 22:1993;35-44
104. Milicevic N.M., Appasamy P., Colic M., Milicevic Z. Immunocytochemical demonstration of prostaglandin synthase (cyclooxigenase) in thymic macrophages of normal and cyclosporin-treated rats. Immunobiology. 190:1994;376-384
105. Milicevic Z., Milicevic N.M. Enzyme histochemical profile of macrophages in the rat thymus after the application of cyclophosphamide. Thymus. 16:1990;59-62
106. Milicevic Z., Colic M., Milicevic N.M. Organization of thymic epithelial cells in cyclosporin-treated rats. Light microscopic immunohistochemical study. Thymus. 17:1991;75-79
107. Milicevic Z., Zivanovic V., Torodovic J., Colic M., Kamperdijk E.W.A., Hoefsmit E.C.M., Milicevic N.M. Differential effect of cyclosporin application on epithelial cells of the rat thymus. Immunohistochemical study. J. Comp. Pathol. 106:1992;25-35
108. Mueller P.W., Delaney V., Macneil M.L., Caudill S.P., Steinberg K.K. Indicators of acute renal-transplant rejection in patients treated with cyclosporine. Clin. Chem. 36(suppl. 5):1990;759-764
109. Mulder GJ. Introduction. In: Conjugation Reactions in Drug Metabolism. Mulder ed. Taylor and Francis, London, 1990, p. 14 (Chapter 1).
110. Myers B.D., Sibley R., Newton L., Tomlanovich S.J., Boshkos C., Stinson E., Luetscher J.A., Whitney D.J., Krasny D., Coplon N.S. The long-term course of cyclosporine-associated chronic nephopathy. Kidney Int. 33:1988;590-601
111. Nebert D.W., Nelson D.R., Coon M.J., Estabrook R.W., Feyereien R., Fuji-Kuriyama Y., Gonzales F.J., Guengerich F.P., Gunsalus I.C., Johnson E.F., Loper J.C., Stato R., Waterman M.R., Wayman D.J. The P450 superfamily. update on new sequences gene mapping and recommended nomenclature DNA Cells Biol. 10:1991;1-14
112. Neild G.H., Taube D.H., Hartley R.B., Bignardi L., Cameron J.S., Williams D.G., Ogg C.S., Rudge C.J. Morphological differentiation between rejection and cyclosporin nephrotoxicity in renal allografts. J. Clin. Pathol. 39:1986;152-159
113. Neto A.B., Haapalainen E., Ferreira R., Feo C.F., Misiako E.P., Vennarecci G., Porcu A., Dib S.A., Golbenberg S., Gomes P.O., Nigro A.T. Metabolic and ultrastructural effects of cyclosporin A on pancreatic islets. Tranpl. Int. 12(3):1999;208-212
114. Nooter K., Sonneveld P. Pharmacokinetics of cyclosporine A. dependence on route of administration and drug dose. Preclinical studies in the rat Modern Trends Clin. Immunosup. 83:1983;215-219
115. Nussemblatt R.B. The use of cyclosporine in ocular inflammatory disorders. Transplant. Proc. 2:1988;114-121
116. Ong A.C.M., Fine L.G. Tubular-derived growth factors and cytokines in the pathogenesis of tubulointerstitial fibrosis. implications for human renal disease progression Am. J. Kidney Dis. 23:1994;205-209
117. Öst L. Impairment of prednisolone metabolism by cyclosporine treatment in renal graft recipients. Transplantation. 44:1987;533-535
118. Paine A.J. Current status review. The cytochrome P450 gene superfamily. Int. J. Exp. Pathol. 72:1991;349-363
119. Palay D.A., Cluff C.W., Wentworth P.A., Ziegler H.K. Cyclosporine inhibits macrophages-mediated antigen presentation. J. Immunol. 136:1986;4348-4353
120. Pang K.S. Kinetics of conjugation reactions in eliminating organs. Conjugation Reactions Drug Metab. 2:1990;5-40
121. Parra Cid T., Conejo Garcia J.R., Carballo Alvarez F., De Arriba G. Antioxidant nutritients protect against cyclosporine A nephrotoxicity. Toxicology. 189:2003;99-111
122. Pastorino J.G., Chen S.T., Tafani M., Snyder J.W., Faber J.L. The over expression of Bax produces cell death upon induction of the mitochondrial permeability transition. J. Biol. Chem. 273:1998;7770-7775
123. Penn I. Cancers following cyclosporine therapy. Transplantation. 43(suppl. 1):1987;32-35
124. Perico N., Detcheva A., Khalil E.I., Remuzzi G. Cyclosporine induces glomerulosclerosis. three-dimensional definition of the lesions in a rat model of renal transplant Kidney Int. 49:1996;1283-1295
125. Pichard L., Fabre I., Domergue J., Joyeux H., Maurel P. Effect of FK-506 on human hepatic cytochromes P-450. interaction with CyA Transplant. Proc. 23(suppl. 6):1991;2791-2793
126. Pickrell M.D., Sawers R., Michael J. Pregnancy after renal transplantation. severe intrauterine growth retardation during treatment with cyclosporine A Br. Med. J. 296:1988;825-836
127. Polson R.J., Powel-Jackson P.R., Williams R. Convulsion associated with cyclosporine A in renal transplant recipients. Br. Med. J. 290:1985;1003-1010
128. Provencer S.J., Demers C., Bastien M.C., Villeneuve J.P., Gascon-Barre' M. Effects of cyclosporine A on cytochrome P-450-mediated drug metabolism in the partially hepatectomized rat. Drug Metab. Dispos. 27(suppl. 4):1999;449-455
129. Quesniaux V.E., Schreier M.H., Wenger R.M., Hiestand P.C., Harding M.W., Van Regenmortec M.H. Cyclophien binds to the region of cyclosporine involved in its immunosuppressive activity. Eur. J. Immunol. 17(suppl. 9):1987;1359-1365
130. Reeves R.A., Shapiro A.P., Thompson M.E., Johnsen A.M. Loss of nocturnal decline in blood pressure after cardiac transplantation. Circulation. 73:1986;401-408
131. Reynolds N.J., Al-Daraji W.I. Calcineurin inhibitors and sirolimus. mechanisms of action and applications in dermatology Rev. Clin. Exp. Dermatol. 27:2002;555-561
132. Rezzani R., Rodella L., Corsetti G., Ventura R.G. Immunohistochemical study of cyclosporin A on rat thymus after various treatment times. J. Biol. Res. 70:1994;119-123
133. Rezzani R., Rodella L., Corsetti G., Ventura R.G. Effects of cyclosporine A on some accessory cells in rat thymus. Int. J. Exp. Pathol. 75:1995;247-254
134. Rezzani R., Rodella L., Corsetti G., Ventura R.G. Thymic depletion of macrophages by dichloromethylendiphosphonate encapsulated in liposomes. Arch. Histochem. Cytochem. 58:1995;427-433
135. Rezzani R., Rodella L., Milanesi S., Bianchi R. Immunohistochemical characterization of thymic macrophages in normal and treated rats. a differential sensitivity to cyclosporine A Int. J. Exp. Pathol. 77:1996;191-196
136. Rezzani R., Rodella L., Bianchi R. Effect of combined cyclosporine A and liposome encapsulated dichloromethylene diphosphonate on the organisation of the rat thymus. evidence for a role of macrophages in guiding the post cyclosporine A thymic reorganisation Int. J. Immunopharmacol. 20:1998;183-192
137. Rezzani R., Rodella L., Bianchi R. Cyclosporine A affects the organization of cytoskeletal fibrillar proteins in rat thymus. Acta Histochem. 102:2000;57-67
138. Rezzani R., Rodella L., Corsetti G., Bianchi R. Does methylene blue protect the kidney tissues from damage induced by cyclosporine A treatment? Nephron. 89:2001;329-336
139. Rezzani R., Rodella L., Bianchi R. Melatonin antagonises the cyclosporine A immunosuppressive effects in rat thymuses. Int. Immunopharmacol. 1:2001;1615-1619
140. Rezzani R., Rodella L., Dessy C., Daneau G., Bianchi R., Feron O. Changes in Hsp90 expression determine the effects of cyclosporine a on the NO pathway in rat myocardium. FEBS Lett. 552:2003;125-129
141. Rezzani R., Corsetti G., Rodella L., Bianchi R. Cyclosporine-A treatment prevents apoptosis in rat lumbar ganglion cells. Acta Histochem. 106:2004;129-135
142. Rhodin JAG. Histology. A text and Atlas. Oxford University Press, London, 1974, pp. 150-151.
143. Rogers A.J., Yoshimura N., Kerman R.H., Kahan B.D. Immunopharmacodynamic evalutation of cyclosporine-treated renal allograft recipients. Transplantation. 38:1984;657-664
144. Rosano T.G., Freed B.M., Cerilli J., Lempert N. Immunosuppressive metabolites of cyclosporine in the blood of renal allograft recipients. Transplantation. 42:1986;262-267
145. Rubin A.M., Kang H. Cerebral blindness and encephalopathy with cyclosporin A toxicity. Neurology. 37:1987;1072-1076
146. Ryffel B. Experimental Toxicological Studies with Cyclosporin A. Elsevier Biomedical Press, Amsterdam, 1982, pp. 45-75.
147. Ryffel B., Deyssenroth H., Borel J.F. Cyclosporin A. effects on the mouse thymus Agent Act. 11:1981;373-379
148. Savino W., Dardenne M., Papiernik M., Bach J.F. Thymic hormone-containing cells. Characterization and localization of serum thymic factor in young mouse thymus studied by monoclonal antibodies. J. Exp. Med. 165:1982;628-633
149. Scheiber S.L., Crabtree G.R. The mechanism of action of cyclosporin A and FK506. Rev. Immunol. Today. 13(suppl. 4):1992;136-142
150. Schuurman H.J., Wijngaert F.P., Delvoye L., Broekhuizen R., Mcclure J.E., Goldstein A.L., Kater L. Heterogeneity and age dependency of human thymus reticulo-epithelium in production of thymosin components. Thymus. 7:1985;13-23
151. Schuurman H.J., Van Loveren H., Rozing J., Van Dijk A., Loeber J.G., Vos J.G. Cyclosporin and the rat thymus. An immunohistochemical study. Thymus. 16:1990;235-254
152. Shaw L.M. Cyclosporine metabolites. are they active? Clin. Chem. 36(suppl. 2):1990;187-191
153. Shaw A.S., Dustin M.L. Making the T cell receptor go the distance. a topological view of T cell division Immunology. 6(suppl. 4):1997;361-369
154. Shinozawa T., Beschorner W.E., Hess A.D. The thymus and prolonged administration of cyclosporine. Irreversible immunopathologic changes associated with autologous pseudo-graft-vs.-host disease. Transplantation. 50:1990;106-111
155. Showstack J., Katz P., Amend W., Berstein L., Lipton H., O'leary M., Bindman A., Salvatierra O. The effect of cyclosporine on the use of hospital resources for kidney trasplantation. New Engl. J. Med. 321:1989;1086-1092
156. Sibley R.K., Rynasiewiez J., Ferguson R.M., Fryd D., Sutherland D.E., Simmons R.L., Najarian J.S. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery. 94:1983;225-230
157. Simpson J.G., Blair J.T., Whiting P.H., Thomson A.W. Cyclosporin A-induced renal proximal tubular damage. IRCS Med. Sci. 9:1981;562-563
158. Singer D.R., Markandu N.D., Buckley M.G., Miller M.A., Cappuccio F.P., Murday A., Sagnella G.A., Lachno D.R., Yacoub M.H., Mac Gregor G.A. Blood pressure and endocrine responses to changes in dietary sodium intake in cardiac transplant recipients. Implications for the control of sodium balance. Circulation. 89(suppl. 3):1994;1153-1159
159. Sorokin R., Kimura H., Schroder K., Wilson D.H., Wilson D.B. Cyclosporine-induced autoimmunity. Conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J. Exp. Med. 164:1986;1615-1621
160. Steiner J.P., Dawson T.M., Fotuhi M. High brain density of the immunophilin FKBP colocalized with calcineurin. Nature. 358:1992;584-587
161. Stoddard B.L.Z., Flick K.E. Calcinuerin-immunosuppressor complexes. Curr. Opin. Struct. Biol. 6:1996;770-775
162. Strom E.H., Epper R., Mihatsch M.J. Cyclosporin-associated arteriolopathy. the renin producing vascular smooth muscle cells are more sensitive to cyclosporin toxicity Clin. Nephrol. 43:1995;226-235
163. Strzelecki T., Kumar S., Khauli R., Menon M. Impairment by cyclosporine of membrane-mediated functions in kidney mitochondria. Kidney Int. 34:1988;234-240
164. Sweny P., Tidman N. The effect of cyclosporin A on peripheral blood T cell subpopulations in renal allografts. Clin. Exp. Immunol. 47:1982;445-448
165. Takeya M., Hsiao L., Shimozawa Y., Takanashi K. Heterogeneity of rat macrophages recognized by monoclonal antibodies. An immunohistochemical and immunoelectronmicroscopic study. J. Histochem. Cytochem. 37:1989;635-641
166. Taler S.J., Textor S.C., Canzarello V.J., Schwartz L. Cyclosporin-induced hypertension. Incidence, pathogenesis and management. Drug Safety. 20(suppl. 8):1999;437-449
167. Tanaka M., Shinohara K., Fukumoto T., Tanaka H., Kaneko T. Effect of cyclosporin A on rat thymus. time course analysis by immunoperoxidase technique and flow cytofluorometry Clin. Exp. Immunol. 72:1988;216-221
168. Tanaka Y., Mamalaki C., Stockinger B., Kioussis D. In vitro negative selection of αβ T cell receptor transgenic thymocytes by conditionally immortalized thymic cortical epithelial cell lines and dendritic cells. Eur. J. Immunol. 23:1993;2614-2622
169. Textor S.C., Canzanello V.J., Taler S.J. Cyclosporine-induced hypertension after transplantation. Mayo Clin. Proc. 69:1994;1182-1193
170. Thomson A.W. The effects of cyclosporin A on non-T cell components of the immune system. J. Autoimmun. 5:1992;167-176
171. Thomson A.W., Whiting P.H., Cameron I.D., Lessels S.E., Simpson J.G. A toxicological study in rats receiving immunotherapeutic doses of cyclosporin A. Transplantation. 31:1981;121-128
172. Thomson C.B., June C.H., Sullivan K.M., Thomas E.D. Association between cyclosporine in neurotoxicity and hypomagnesemia. Lancet. 2:1984;116-120
173. Tortorice K.L., Heim-Duthoy K.L., Awni W.M., Venkateswara R., Kasiske B.L. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther. Drug Monit. 12:1990;321-328
174. Van De Wijngaert F.P., Kendall M.D., Schuurman H.J., Rademakers L.H.P.M., Kater L. Heterogeneity of epithelial cells in the human thymus. An ultrastructural study. Cell Tissue Res. 237:1984;227-237
175. Vellodi A., Jayatunga R., Hugh-Jones K. Hemiplegia and focal convulsions as a manifestation of cyclosporine A toxicity. J. Clin. Pharmacol. 27:1987;914-915
176. Verdecchia P., Schillaci G., Guerrieri M., Gatteschi C., Benemio G., Boldrini F., Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 81:1990;528-536
177. Verpooten G.A., Wybo I., Pattyn V.M., Hendrix P.G., Giuliano R.A., Nouwen
178. Vogt D.P., Ledermar R.J., Carey W.D., Broughan T.A. Neurologic complications of liver transplantation. Transplantation. 45:1988;1057-1061
179. Wagner O., Schreiber E., Hetz F., Maurer G. Tissue distribution, disposition, and metabolism of cyclosporin A metabolites in rabbit and man. Drug Metab. Disp. 15:1987;377-383
180. Watkins P.B. The role of cytochrome P-450 in cyclosporine metabolism. J. Am. Acad. Dermatol. 6:1990;1301-1309
181. Wenzel-Seifert K., Harwig S., Keller F. Fulminant calcinosis in two patients after kidney transplantation. Am. J. Nephrol. 11:1991;497-503
182. Whiting P.H., Thomson A.W., Blair J.T., Simpson J.G. Experimental cyclosporin A nephrotoxicity. Br. J. Exp. Pathol. 63:1982;88-93
183. Whiting P.H., Simpson J.G., Davidson R.J.L., Thomson A.W. Pathological changes in rats receiving cyclosporin A at immunotherapeutic dosage for 7 weeks. Br. J. Exp. Pathol. 64:1983;437-444
184. Williams R.T. The metabolism or foreign compounds and the detoxication mechanism. Detoxication Mech. 21:1959;717-740
185. Wolf A., Trendelenburg C.F., Diez-Fernandez C., Prieto P., Houy S., Trommer W.E., Cordier A. Cyclosporin A-induced oxidative stress in rat hepatocytes. J. Pharmacol. Exp. Ther. 280:1997;1328-1334
186. Yamaguchi J., Teraoka S., Yagisawa T., Takahashi K., Toma H., Ota K. Ultrastructural study of cyclosporine-associated arteriolopathy in renal allografts. Transplant. Proc. 21:1989;1517-1523
187. Yee G.C., McGuire T.R. Pharmacokinetic drug interaction with cyclosporine. Clin. Pharmacokinet. 19:1990;319-333
188. Yoshinoya S., Yamamato K., Mitamura T., Takeuchi A., Takahashi K., Miyamato T. Successful treatment of rheumatoid arthritis with low dose cyclosporine A. Transplant. Proc. 20:1988;243-247
189. Zeevi A., Eiras G., Burckart G., Marowka L., Venkataramanan R., Wang C.P., Van Thiel D.H., Murase N., Starzi T.E., Duquesnoy R. Immunosuppressive effect of cyclosporine metabolites from human bile on alloreactive T cells. Transplant. Proc. 20(suppl. 2):1988;115-121